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Aim: To assess acute and late toxicity of hypofractionated radiotherapy, its efﬁcacy and
impact on quality of life in patients with low-risk prostate cancer.
Materials and methods: Since August 2006 to October 2007, 15 prostate cancer patients with
favorable clinical features, aged 54–74 years (mean 67 years) entered the study. Tumor stage
in  the majority (73%) of patients was T2a, the mean pretreatment PSA value was 7.2 ng/ml
(range 5–10.9 ng/ml). The study group was treated 3 times a week with 4 Gy per fraction to
the  total dose of 60 Gy within 5 weeks. 3D conformal treatment planning was used with no
ﬁducial markers. Acute and late toxicity was evaluated using modiﬁed EORTC/RTOG/LENT
scoring systems. Patients regularly ﬁlled the EORTC QLQ-PR25 questionnaires.
Results: All patients completed radiotherapy according to the plan. During radiotherapy, 26%
of  patients had grade 1–2 rectal symptoms. The incidence of acute urinary toxicity score was
26%,  60%, and 14% for grade 0–1, 2 and 3, respectively. One year after RT, the incidence of
grade 2 GI toxicity was 27%, which was the reason for an early closure of the accrual. Grade
2  late urinary toxicity was noted in 20% of patients. The mean PSA level was 0.61 ng/ml after
24  months and 0.47 ng/ml after 36 months (range: 0.06–1.54 ng/ml).
Conclusions: Low number of patients does not allow to determine the inﬂuence of hypofrac-
tionation on unsatisfactory tolerance of this regimen. Suboptimal (from the present day’sperspective) target localiz
expected late GI reactions
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Table 1 – Clinical characteristics of patients.
Age (year)
<70 years 7 (47%)
≥70 years 8 (53%)
T stage
T1c 1 (7%)
T2a 12 (80%)
T2b 2 (13%)
PSA
<7 ng/ml 7 (47%)
≥7 ng/ml 8  (53%)
tion of ﬁelds and isocenter positions. Patients were initiallyGleason score
2–4 6  (40%)
5–6 9 (60%)
1.  Background
Following the publication of Brenner and Hall1 that pos-
tulated high sensitivity of prostate cancer to fraction size
(alpha/beta value of 1.5 Gy {0.8–2.2}), there was an increase
of clinical interest in the use of high fraction doses (hypofrac-
tionation) in curative radiotherapy for prostate cancer.2 The
results of several prospective studies were published, includ-
ing randomized trials that compared standard fractionation
and hypofractionation.3–6 There were also several attempts
to re-evaluate ˛/  ˇ value for prostate cancer, leading to some-
what conﬂicting results,7–12 with most estimates supporting
its low value.7,9–11 The presumed beneﬁt from hypofraction-
ation in prostate cancer that originated from radiobiological
considerations, created the basis for the present study.
2.  Aim
The aim of this study was to assess acute and late toxicity
of hypofractionated radiotherapy, its efﬁcacy and impact on
quality of life.
We  focused on patients with low-risk prostate cancer, hor-
monally naive, to have unbiased observation of PSA dynamic
during follow-up.
3.  Materials  and  methods
3.1.  Clinical  characteristics  of  the  patients
Between August 2006 and October 2007, a prospective pilot
study on hypofractionated radiotherapy in prostate cancer
patients was conducted in Maria Skłodowska-Curie Memo-
rial Cancer Center and Institute, Gliwice Branch. The primary
endpoint was tolerance of treatment, as assessed by recording
acute and late genitourinary and gastrointestinal normal tis-
sue reactions, with biochemical free survival (BFS) being the
secondary endpoint. The Phoenix deﬁnition was used as the
criterion of biochemical failure (BF).13 We planned to enroll
twenty low-risk prostate cancer patients.
Fifteen patients with newly diagnosed prostatic adenocar-
cinoma were ﬁnally enrolled, Gleason score 6 or less, with
PSA mean concentration equal or less than 10 ng/ml (mean
7.2 ng/ml), at early stage of disease according to 6th edi-
tion (2002) of AJCC staging guidelines (Table 1). The routineiotherapy 1 9 ( 2 0 1 4 ) 337–342
diagnostic procedures included TRUS and MRI  spectroscopy
of prostate gland.
Patients who fulﬁlled the trial criteria signed the informed
consent. The institutional bioethical committee approved the
trial design.
3.2.  Radiobiological  considerations
The total dose routinely used for treatment of low-risk
prostate cancer patients in our hospital is 76 Gy in 2 Gy per
fraction. Based on the assumption that ˛/  ˇ for late effects in
organs at risk (OAR) is 6 Gy,14,15 it corresponds to the total
dose of 60.8 Gy/g in 4 Gy per fraction, which was calculated
following the formula proposed by Withers et al.16:
D(4) = D(2) × [{˛/  ˇ + d(2)}:{˛/  ˇ + d(4)}]
D(4) = 76 Gy [{6 + 2}:{6 + 4}]
D(4) = 60.8 Gy
D(4) – total dose for 4 Gy per fraction, ˛/  ˇ – sensitivity of OAR
to fraction dose (assumed 6 Gy).
According to the assumed parameters, the total dose
of 60 Gy given in 4 Gy fractions corresponds to 75 Gy for
late effects in OAR (˛/  ˇ = 6 Gy) and to 94.3 Gy for the tumor
(˛/ˇ = 1.5 Gy).
Based on reports17,18 that 75 Gy (given in 2 Gy per fraction) is
the tolerance dose to small volumes of rectum, it was assumed
that increasing the dose per fraction from 2 to 4 Gy should be
safe for OAR with the total dose of 60 Gy.
The dose volume constraints for 5%, 30% and 40% vol-
ume  of the rectum were: 60 Gy, 56 Gy and 52 Gy, respectively
(for fraction doses of 4 Gy). Those constraints correspond to
V75 ≤ 5%, V70 ≤ 30%, V65 ≤ 40% for conventional fractionation
with a fraction size of 2 Gy. The dose volume constraint for the
bladder was such that no more  than 30% could receive 56 Gy
in 4 Gy per fraction.
3.3.  Treatment
Patients were treated in a supine position, stabilized with a
vacuum mattress and thermoplastic mask with ﬁxed a head,
hips and feet. They were instructed to drink 0.5 l of ﬂuids
one hour before CT scanning. There were no speciﬁc instruc-
tions about the ﬁlling of the rectum, however, patients were
informed how to avoid constipation. Laxatives or alpha antag-
onists were not used prophylactically. Non-contrast CT was
collected every 3 mm.  Clinical target volume was described as
the whole prostate, the irradiated volume consisted of CTV
with 1 cm margin from the rectal wall and 1.5–2 cm margin
in all other directions, which was typical at that time for a
standard fractionation regimen.
The dose was prescribed to the isocenter, we  used the rec-
ommendation from the ICRU Report 62. Only two patients
were treated with IMRT, all the others with conventional 3D
conformal radiotherapy, with 3–7 ﬁelds.
Treatment veriﬁcation consisted of a classical simula-set up according to isocenter positions and in-room lasers.
Before each fraction, kV image  of bone structures of the
pelvis was obtained. The images were then compared with
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Table 2 – Acute GU and GI toxicity of radiation therapy
according to modiﬁed RTOG criteria.20
The severity of
acute reaction
Acute GU Acute GI
Grade 0 2 (13%) 11 (74%)
Grade 1 2 (13%) 2 (13%)
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Fig. 1 – The mean score for two questions from EORTC QLQ
– PR25 questionnaire, range: 1–4, where 1 means never,
2-sometimes, 3-often, 4-very often.Grade 2 9 (61%) 2 (13%)
Grade 3 2  (13%) 0
igitally reconstructed reference radiographs and correction
f the table position was made, when needed.
Patients were treated on linear accelerators equipped with
ulti-leaf collimators. Treatment was delivered with 20 MV
-rays.
The rectum was contoured as a single solid organ from the
ottom of the ischium to the sigmoid ﬂexure, the bladder was
lso contoured as a solid organ.
Acute toxicity of radiation therapy was assessed once a
eek during treatment, one month after completing RT, every
hree months for two years, every six months in the third
ear of follow-up and annually later on. For the evaluation
f acute and late toxicity, we adopted the modiﬁed RTOG and
ENT scales19,20 (Appendix 1 and 2). The modiﬁed LENT scale
ncludes ways of handling and treating the late complications
hich makes it easier to be used in a clinic. The differences
etween the original RTOG classiﬁcation21 and the modiﬁed
cale for acute radiation toxicity according to the paper by
torey20 are less pronounced (Appendix 1). It divides rectal
leeding into grade 2 (if “mild”) and grade 3 (if “requiring
ne transfusion”). For acute GU, it adds the need for tempo-
ary catheterization and puts “infrequent” gross hematuria as
rade 2. It lets the need for transfusion (only if one) to be placed
s grade 3 urinary acute symptoms.
The quality of life was assessed using EORTC QLQ-C30-PR25
uestionnaires. The permission for use of EORTC question-
aires was obtained before the trial.
The questionnaires were ﬁlled by our group of patients
eekly, starting from the week preceding the beginning of
heir treatment. It was continued during follow-up, at each
isit.
Serum PSA measurements were performed at each follow-
p visit.
.4.  Statistical  tests
o check if a variable fulﬁlls the criteria of normal distribution
est W Shapiro–Wilk and K–S were used, non-parametric sta-
istical tests such as ANOVA, Kruskal–Wallis for multiple and
 Mann–Whitney test for two samples.
.  Results
edian follow-up was 29 months (range: 18.5–37). The most
requent were urinary (GU) acute side effects, with 74% of them
ith grade 2 or higher toxicity. At the same time gastrointesti-
al (GI) acute symptoms were mild, with no grade 2 reactions
nd only 13% of grade 1 acute reaction (Table 2).
In general, one month after the end of radiation ther-
py all the symptoms of acute GI disappeared, and a majorimprovement was observed among the patients suffering from
urinary reactions. Only two patients with residual grade 1 and
one with grade 2 symptoms were seen.
An interim analysis after one year revealed a higher rate
of late rectal injury than expected, resulting in an early clo-
sure of the trial after recruitment of 15 patients. Such decision
was also based on the observed severity of late GI toxicity as
scored using modiﬁed LENT criteria (Table 3). We noted that
the symptoms of rectal bleeding subsided at a longer follow-
up, although at 24–36 months after radiotherapy there were
still more  frequent than expected (Fig. 1 and Table 3).
In the following months, the decrease of its intensity was
observed (Table 3). At the third year of follow-up, nocturia,
incontinence requiring the use of pads were still observed
with 22% and 14% patients suffering from late GU toxicity
grade 1 and 2, respectively. Twenty-one percent of patients
complained of slight rectal bleeding at the thirtieth month of
follow-up. Fig. 1 illustrates the mean score from EORTC QLQ
PR 25 questionnaires in the following weeks of treatment and
follow-up. One year after radiotherapy, one patient was diag-
nosed with sigmoid colon cancer, which eventually was fatal.
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Table 3 – Late GU and GI toxicity of radiation therapy according to modiﬁed LENT criteria.19,20
The severity of late reaction 9 mth  12 mth  15 mth  24 mth  30 mth
Late GU toxicity
No at risk 15 15 14 14 14
0 60% 66% 57% 79% 57%
1 20% 13% 22% 14% 22%
2 13% 20% 14% 7% 14%
No data 7% 7% 7%
Late GI toxicity
No at risk 15 15 14 14 14
0 73% 73% 72% 79% 72%
27%
1 7% 
2 13%
No data 7% 
We  searched for possible connection between the side
effects and co-morbidities. We gathered data about history
of hemorrhoids, diabetes, hypertension and 1-inhibitors,
anticoagulants, but no clear correlations were found. Higher
average volume of the bladder that received 56 Gy (V70 Gy –
equivalent dose at 2 Gy per fraction, or EQD2) was recorded
in patients with peak grade 1 or 2 acute toxicity, compared to
grade 0 (23% vs. 4%, p = 0.027 U-Mann–Whitney test).
The review of contouring the organs at risk revealed the
wide range of bladder volumes. Although all the patients were
given the same instructions on drinking ﬂuids and not to void
for half an hour before the irradiation, we  found great differ-
ences among the volumes of their bladders at the CT: starting
from 108 to 623 cm3 (mean value 312 cm3). A similar hetero-
geneity was found in rectal volumes contoured from sigmoid
colon to the anal verge: 44–193 cm3 (mean value 89 cm3).
The PSA concentration decreased with exception of one
patient (Fig. 2).We observe a gradual constant decrease with mean value
after 30 months: 0.63 (range: 0.05–2.6) ng/ml, 0.47 ng/ml (range:
0.06–1.54 ng/ml) after 36 months. There is only one patient
with PSA bounce to the value of 5.19 ng/ml, which occurred
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Fig. 2 – The mean value of serum PSA measurements b14% 21% 21%
7% 0  0
7% 7%
18 months after RT, with 1.54 ng/ml six months before the
bounce. The additional diagnostic exams were performed
including bone scintigraphy and spectroscopy MRI. His last
blood test for PSA was 0.64 ng/ml at 30 months after he
completed RT. There has been no biochemical recurrence diag-
nosed so far.
5.  Discussion
5.1.  Toxicity  of  treatment
Several treatment modalities are currently being used in
therapy for low-risk prostate cancer. Active surveillance, rad-
ical prostatectomy, fractionated radiotherapy are among the
options. Fractionated radiotherapy can be used as a sole treat-
ment or in combination with brachytherapy. HDR or LDR
brachytherapy alone is a valid option. The morbidity of these
methods has a major impact on the selection of treatment.
The assessment and comparison of adverse effects in these
methods is difﬁcult, particularly outside the prospective clin-
ical trials. Diverse scoring systems are used that often disable
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irect comparisons of the outcome. The incidence of late GI
oxicity observed in this series was higher than expected,
articularly at 12 months after treatment. It exceeded the
umbers reported by most authors4,22–26 with the reported
ate of grade 2 late reactions below 10%, compared to 27% in
he present series. This necessitated an early closure of the
tudy. Some studies that recorded a higher than average rate
f late GI reactions used higher than the standard equiva-
ent doses. Akimoto et al.27 observed relatively high late GI
eactions among patients treated to 69 Gy in 3 Gy per frac-
ion that would correspond to 77.6 Gy EQD2 for late reactions
assuming ˛/  ˇ =6 Gy). We note that the EQD2 dose used in this
tudy was comparable to the present one. Statistically signiﬁ-
ant increase in acute GI and GU toxicity was observed in the
roup of patients treated with hypofractionated radiotherapy
n comparison with a conventional treatment in a random-
zed trial of Lukka et al.,4 although it did not result in higher
ate toxicity rates. Acute GI, but not GU, toxicity scores were
igher in the experimental arm in the Australian randomized
rial.5 At two and three years of follow up, total GU symptoms
ere signiﬁcantly worse in the hypofractionated RT arm, with
o statistically signiﬁcant difference in GI symptoms at follow
p, with the exception of urgency of defecation. The ﬁve-year
esults of a randomized trial previously published by Pollack
t al.3 was presented at the 2011 ASTRO Conference,28 with a
igniﬁcantly higher grade 2 or higher GU late reactions in the
ypofractionation group.
.2.  Radiobiological  considerations
he higher than expected rate of late GI reactions necessi-
ates caution with respect to the future assumptions of the
/  ˇ value of late reactions of the rectum. The outcome of the
tudy may suggest that the assumed ˛/  ˇ value of 6 Gy was
oo high. A relatively wide of ˛/  ˇ values for late reactions
f the rectum is provided in the literature14,15,29 with 6 Gy
eing apparently at the upper end of the postulated ranges.
he outcome of the study may suggest that more restrictive
ssumptions (e.g. ˛/  ˇ = 3 Gy) should be used in future attempts
o estimate the late effects in the rectum. For the same reason,
ose constraints for radiation treatment given in 4 Gy fractions
hat were used in the present study cannot be further recom-
ended. Also, the proposed treatment schedule (60 Gy in 4 Gy
er fraction) may have to be modiﬁed if lower ˛/  ˇ values for
he rectum are considered. The physical dose of 60 Gy would
orrespond to 84 Gy in 2 Gy equivalents assuming ˛/  ˇ = 3 Gy for
ate effects. This may be too intense, particularly considering
adiation techniques that were used.
.3.  Quality  assurance  and  treatment  technique
n this series of patients the interfraction patient set-up was
ased on kV imaging of bone structures. Such a technique
ight be considered obsolete according to the present-day
tandards. Routine use of ﬁducial markers implanted to the
rostate and advanced on-board imaging (e.g. cone-beam CT)
ay contribute to a better treatment precision.23,24,30–32
Considering the outcome in the present series, one may
ostulate that kV imaging of bone structures may appear
nsufﬁcient for treatment set-up of prostate cancer patientstherapy 1 9 ( 2 0 1 4 ) 337–342 341
whenever higher than standard fraction or total doses are
used.
Modern technique, e.g. IMRT plans instead of 3DCRT, and
daily localization with advanced systems based on ﬁducial
markers used in studies on hypofractionated radiation ther-
apy, seem to be necessary to secure its satisfactory tolerance.
6.  Conclusions
Low number of patients does not allow to determine the inﬂu-
ence of hypofractionation on unsatisfactory tolerance of this
regimen. Suboptimal (from the present day’s perspective) tar-
get localization (no ﬁducial markers) could potentially explain
higher than expected late GI reactions in our series.
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Appendix  A.  Supplementary  data
Supplementary data associated with this article can be
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